Activation of latent transforming growth factor-β1 by nitric oxide in macrophages: Role of soluble guanylate cyclase and MAP kinases

Wound Repair and Regeneration

Volumn 17, Issue 4, 2009, Pages 578-588

  Metukuri, Mallikarjuna Reddy ^a   Namas, Rajaie ^a   Gladstone, Chase ^a   Clermont, Thierry ^a   Jefferson, Bahiyya ^a   Barclay, Derek ^a   Hermus, Linda ^a   Billiar, Timothy R ^a   Zamora, Ruben ^a   Vodovotz, Yoram ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 8 BROMO CYCLIC GMP; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CYCLIC GMP; GUANYLATE CYCLASE; GUANYLATE CYCLASE INHIBITOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N ACETYL S NITROSOPENICILLAMINE; NITRIC OXIDE; RNA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOCYTOCHEMISTRY; MACROPHAGE; MOUSE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; WESTERN BLOTTING; WOUND HEALING;

ANIMALS; CELL LINE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GUANYLATE CYCLASE; MACROPHAGES; MICE; NITRIC OXIDE; SECOND MESSENGER SYSTEMS; TRANSFORMING GROWTH FACTOR BETA1; WOUND HEALING;

EID: 67651173134     PISSN: 10671927     EISSN: 1524475X     Source Type: Journal    
DOI: 10.1111/j.1524-475X.2009.00509.x     Document Type: Article

References (33)

1. Hart J. Inflammation. 1: its role in the healing of acute wounds. J Wound Care 2002 11 : 205 9.
2. Schwentker A, Vodovotz Y, Weller R, Billiar TR. Nitric oxide and wound repair: role of cytokines? Nitric Oxide 2002 7 : 1 10.
3. Roberts AB, Sporn MB. Transforming growth factor-β. In : Clark RAF, editor. The molecular and cellular biology of wound repair. New York : Plenum Press, 1996 : 275 308.
4. Rifkin DB. Latent transforming growth factor-beta (TGF-beta) binding proteins: orchestrators of TGF-beta availability. J Biol Chem 2005 280 : 7409 12.
5. Ten Dijke P, Hill CS. New insights into TGF-beta-Smad signalling. Trends Biochem Sci 2004 29 : 265 73.
6. Vodovotz Y, Chesler L, Chong H, Kim SJ, Simpson JT, DeGraff W, Cox GW, Roberts AB, Wink DA, Barcellos-Hoff MH. Regulation of transforming growth factor-β1 by nitric oxide. Cancer Res 1999 59 : 2142 9.
7. Barcellos-Hoff MH, Dix TA. Redox mediated activation of latent transforming growth factor-β1. Mol Endocrinol 1996 10 : 1077 83.
8. Murad F. Shattuck lecture. Nitric oxide and cyclic GMP in cell signaling and drug development. N Engl J Med 2006 355 : 2003 11.
9. Levonen AL, Patel RP, Brookes P, Go YM, Jo H, Parthasarathy S, Anderson PG, Darley-Usmar VM. Mechanisms of cell signaling by nitric oxide and peroxynitrite: from mitochondria to MAP kinases. Antioxid Redox Signal 2001 3 : 215 29.
10. Kim S-J, Denhez F, Kim KY, Holt JT, Sporn MB, Roberts AB. Activation of the second promoter of the transforming growth factor-beta1 gene by transforming growth factor-Beta1 and phorbol ester occurs through the same target sequences. J Biol Chem 1989 264 : 19373 8.
11. El-Sherif AM, Seth R, Tighe PJ, Jenkins D. Decreased synthesis and expression of TGF-beta1, beta2, and beta3 in epithelium of HPV 16-positive cervical precancer: a study by microdissection, quantitative RT-PCR, and immunocytochemistry. J Pathol 2000 192 : 494 501.
12. Horimoto M, Kato J, Takimoto R, Terui T, Mogi Y, Nitsu Y. Identification of a transforming growth factor beta-1 activator derived from a human gastric cancer cell line. Br J Cancer 1995 72 : 676 862.
13. Barcellos-Hoff MH. Latency and activation in the control of TGF-beta. J Mammary Gland Biol Neoplasia 1996 1 : 353 63.
14. Mazzieri R, Munger JS, Rifkin DB. Measurement of active TGF-beta generated by cultured cells. Methods Mol Biol 2000 142 : 13 27.
15. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGF beta activation. J Cell Sci 2003 116 (Part 2) : 217 24.
16. Zamora R, Vodovotz Y. Transforming growth factor-β in critical illness. Crit Care Med 2005 33 : S478 81.
17. Chong H, Vodovotz Y, Cox GW, Barcellos-Hoff MH. Immunocytochemical detection of latent TGF-β activation in cultured macrophages. J Cell Physiol 1999 178 : 275 83.
18. Messmer UK, Ankarcrona M, Nicotera P, Brune B. p53 expression in nitric oxide-induced apoptosis. FEBS Lett 1994 355 : 23 6.
19. Cano E, Mahadevan LC. Parallel signal processing among mammalian MAPKs. Trends Biochem Sci 1995 20 : 117 22.
20. Komalavilas P, Shah PK, Jo H, Lincoln TM. Activation of mitogen-activated protein kinase pathways by cyclic GMP and cyclic GMP-dependent protein kinase in contractile vascular smooth muscle cells. J Biol Chem 1999 274 : 34301 9.
21. Kim SO, Xu Y, Katz S, Pelech S. Cyclic GMP-dependent and -independent regulation of MAP kinases by sodium nitroprusside in isolated cardiomyocytes. Biochim Biophys Acta 2000 1496 : 277 84.
22. Varma S, Breslin JW, Lal BK, Pappas PJ, Hobson RW, Duran WN. p42/44MAPK regulates baseline permeability and cGMP-induced hyperpermeability in endothelial cells. Microvasc Res 2002 63 : 172 8.
23. Oliveira CJ, Schindler F, Ventura AM, Morais MS, Arai RJ, Debbas V, Stern A, Monteiro HP. Nitric oxide and cGMP activate the Ras-MAP kinase pathway-stimulating protein tyrosine phosphorylation in rabbit aortic endothelial cells. Free Radic Biol Med 2003 35 : 381 96.
24. Hodges RR, Shatos MA, Tarko RS, Vrouvlianis J, Gu J, Dartt DA. Nitric oxide and cGMP mediate alpha1D-adrenergic receptor-stimulated protein secretion and p42/p44 MAPK activation in rat lacrimal gland. Invest Ophthalmol Vis Sci 2005 46 : 2781 9.
25. Yoshioka Y, Yamamuro A, Maeda S. Nitric oxide/cGMP signaling pathway protects RAW264 cells against nitric oxide-induced apoptosis by inhibiting the activation of p38 mitogen-activated protein kinase. J Pharmacol Sci 2006 101 : 126 34.
26. Dudnikova GN, Zaidenberg MV. Effect of cyclic guanidine monophosphate on experimental wound healing. Biull Eksp Biol Med 1980 89 : 543 5.
27. Hsu YC, Hsiao M, Chien YW, Lee WR. Exogenous nitric oxide stimulated collagen type I expression and TGF-beta1 production in keloid fibroblasts by a cGMP-dependent manner. Nitric Oxide 2007 16 : 258 65.
28. Hirano S, Rees RS, Gilmont RR. MAP kinase pathways involving hsp27 regulate fibroblast-mediated wound contraction. J Surg Res 2002 102 : 77 84.
29. Vodovotz Y. Control of nitric oxide production by transforming growth factor-b1: mechanistic insights and potential relevance to human disease. Nitric Oxide 1997 1 : 3 17.
30. Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol 2000 1 : 169 78.
31. Otsuka M, Tsuchiya S, Aramaki Y. Involvement of ERK, a MAP kinase, in the production of TGF-beta by macrophages treated with liposomes composed of phosphatidylserine. Biochem Biophys Res Commun 2004 324 : 1400 5.
32. Hanafusa H, Ninomiya-Tsuji J, Masuyama N, Nishita M, Fujisawa J, Shibuya H, Matsumoto K, Nishida E. Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-beta-induced gene expression. J Biol Chem 1999 274 : 27161 7.
33. Barcellos-Hoff MH, Ehrhart EJ, Kalia M, Jirtle R, Flanders K, Tsang ML-S. Immunohistochemical detection of active transforming growth factor-β in situ using engineered tissue. Am J Pathol 1995 147 : 1228 37.